Prejuvenation and the New Pro-Aging Reader

Prejuvenation is a word with no literature. It appears in clinic waiting rooms and in the caption of a hundred thousand videos, and it means, roughly, the treatment of a face that has not yet aged in order to prevent it from doing so. There is no clinical definition, no diagnostic threshold, and no trial that tests the category itself. This is worth saying plainly at the start, because most writing on the subject does not say it at all.

What does exist is evidence about the individual interventions that prejuvenation borrows: photoprotection, topical retinoids, barrier care, and a growing and uneven literature on oral supplements. Those can be read honestly. The category cannot.

Begin with the intervention that has the best claim, which is also the least sellable. A randomised trial in Queensland followed more than nine hundred adults for four and a half years and found that daily use of a broad-spectrum sunscreen slowed the visible progression of photoageing, measured by microtopography, independent of age or sun exposure. Nothing else in this field has a result of that shape. It is also the only intervention here that requires no appointment, no prescription and no budget worth mentioning.

Retinoids come second, and with more caveats. A double-blind vehicle-controlled study from 1988 established that topical tretinoin improves photoaged skin over months of use. It also established the cost: irritation, photosensitivity, and a requirement for persistence that most people do not sustain. The trial did not study twenty-eight-year-olds preventing a wrinkle. It studied existing damage, in people who kept going for month after month. Anyone selling a retinoid as insurance rather than repair is selling a different product from the one that was tested.

Barrier care is where the mechanistic tier does most of its work. Humectants and occlusives reduce transepidermal water loss, and a barrier that holds water behaves differently from one that does not. The mechanism is well described. The long-term cosmetic outcome of a decade of good moisturising is not something anyone has run a trial on, and we will not pretend otherwise to fill the gap.

Oral collagen peptides are the newest and the most oversold. A small randomised study published in 2014 reported improved skin elasticity and moisture after eight weeks of supplementation. It is a real result in a small sample, with a commercial interest in the outcome, and it should be read as a hypothesis with a pleasant side effect rather than a settled fact. If a brand tells you this literature is closed, they have not read it.

Two things follow from all of this, and they are less exciting than the word prejuvenation. First, the strongest evidence sits in a habit rather than a purchase. Second, the weakest evidence is attached to the most expensive products, because that is where the margin is.

The new pro-aging reader is not the opposite of the prejuvenation patient. She is the same person after one honest conversation. She is unwilling to be told that ageing is a disease, and equally unwilling to be sold a decade of prevention without a single trial to support the shape of the promise.

What the house recommends, therefore, is unfashionable and cheap: shade, a hat, a sunscreen you will actually wear, a retinoid introduced slowly if your skin tolerates it, and a moisturiser that ends the day with your barrier intact. Everything beyond that is a choice rather than a duty, and should be priced as a choice.

The one thing we will not do is apply a score to a face. There is no number at the end of this essay, and the absence is deliberate. A reader is not a result.